|
Video: What is a Stock Split?
|
|
RedHill Biopharma is a biopharmaceutical company that focuses on commercialization and development of proprietary drugs for gastrointestinal (GI) diseases. The ongoing development programs of Co.'s therapeutic candidates, most in late-stage clinical development, include: RHB-204, which is for the treatment of mycobacterium avium complex disease; RHB-104, which is an investigational drug intended to treat Crohn's disease; RHB-102 (Bekinda®), which is an investigational once-daily bi-modal extended-release oral formulation of ondansetron; and RHB-106, which is an investigational tablet intended for the preparation and cleansing of the GI tract prior to the performance of abdominal procedures. According to our RDHL split history records, Redhill Biopharma Ltd Ramat Gan has had 1 split. | |
|
Redhill Biopharma Ltd Ramat Gan (RDHL) has 1 split in our RDHL split history database. The split for RDHL took place on March 23, 2023. This was a 1 for 40 reverse split, meaning for each 40 shares of RDHL owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 25 share position following the split.
When a company such as Redhill Biopharma Ltd Ramat Gan conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the RDHL split history from start to finish, an original position size of 1000 shares would have turned into 25 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Redhill Biopharma Ltd Ramat Gan shares, starting with a $10,000 purchase of RDHL, presented on a split-history-adjusted basis factoring in the complete RDHL split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/29/2014 |
|
End date: |
04/25/2024 |
|
Start price/share: |
$567.20 |
|
End price/share: |
$0.42 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.93% |
|
Average Annual Total Return: |
-51.42% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$7.34 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
03/23/2023 | 1 for 40 |
|
|